Key result
Severe diastolic dysfunction linked to ~35% higher mortality in HFrEF and HFmrEF.
Why the study?
The role of diastolic dysfunction in the prognostic evaluation of heart failure patients with impaired systolic function remains unclear.
Does severe diastolic dysfunction increase mortality in heart failure patients with mid-range or reduced ejection fraction?
Cohort (n=2,018)
Does severe diastolic dysfunction increase mortality in heart failure patients with mid-range or reduced ejection fraction?
Effect estimate: HR 1.347 (HFrEF); HR 1.358 (HFmrEF)
p-value: p=0.015 (HFrEF); 0.046 (HFmrEF)
Echocardiography-defined severe diastolic dysfunction is an independent predictor of all-cause mortality in patients with both mid-range and reduced ejection fraction heart failure.
May aid risk stratification in HFrEF/HFmrEF; leaves open whether diastolic-targeted therapies improve outcomes.
AIMS: The role of diastolic dysfunction (DD) in prognostic evaluation in heart failure (HF) patients with impaired systolic function remains unclear. We investigated the impact of echocardiography-defined DD on survival in HF patients with mid-range (HFmrEF, EF 41-49%) and reduced ejection fraction (HFrEF, EF < 40%). METHODS AND RESULTS: A total of 2018 consecutive hospitalized HF patients were retrospectively included and divided in two groups based on baseline EF: HFmrEF group (n = 951, aged 69 ± 13 years, 74.2% male) and HFrEF group (n = 1067, aged 68 ± 13 years, 76.3% male). Clinical data were collected and analysed. All patients completed ≥1 year clinical follow-up. The primary endpoint was defined as all-cause death (including heart transplantation) and cardiovascular (CV)-related death. All-cause mortality (30.8% vs. 24.9%, P = 0.003) and CV mortality (19.1% vs. 13.5%, P = 0.001) were significantly higher in the HFrEF group than the HFmrEF group during follow-up [median 24 (13-36) months]. All-cause mortality increased in proportion to DD severity (mild, moderate, and severe) in either HFmrEF (17.1%, 25.4%, and 37.0%, P < 0.001) or HFrEF (18.9%, 30.3%, and 39.2%, P < 0.001) patients. The risk of all-cause mortality [hazard ratio (HR) = 1.347, P = 0.015] and CV mortality (HR = 1.508, P = 0.007) was significantly higher in HFrEF patients with severe DD compared with non-severe DD after adjustment for identified clinical and echocardiographic covariates. For HFmrEF patients, severe DD was independently associated with increased all-cause mortality (HR = 1.358, P = 0.046) but not with CV mortality (HR = 1.155, P = 0.469). CONCLUSIONS: Echocardiography-defined severe DD is independently associated with increased all-cause mortality in patients with HFmrEF and HFrEF.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) conducted a cohort in Heart failure with mid-range or reduced ejection fraction (n=2,018). Severe diastolic dysfunction vs. Non-severe diastolic dysfunction was evaluated on All-cause death (including heart transplantation) and cardiovascular (CV)-related death (HR 1.347 (HFrEF); HR 1.358 (HFmrEF), p=0.015 (HFrEF); 0.046 (HFmrEF)). Severe diastolic dysfunction was independently associated with increased all-cause mortality in patients with HFrEF (HR 1.347, P=0.015) and HFmrEF (HR 1.358, P=0.046) compared to non-severe DD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: